641 related articles for article (PubMed ID: 24459177)
1. The roles of MRP2, MRP3, OATP1B1, and OATP1B3 in conjugated hyperbilirubinemia.
Keppler D
Drug Metab Dispos; 2014 Apr; 42(4):561-5. PubMed ID: 24459177
[TBL] [Abstract][Full Text] [Related]
2. New insights in bilirubin metabolism and their clinical implications.
Sticova E; Jirsa M
World J Gastroenterol; 2013 Oct; 19(38):6398-407. PubMed ID: 24151358
[TBL] [Abstract][Full Text] [Related]
3. Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans.
Yamashiro W; Maeda K; Hirouchi M; Adachi Y; Hu Z; Sugiyama Y
Drug Metab Dispos; 2006 Jul; 34(7):1247-54. PubMed ID: 16624871
[TBL] [Abstract][Full Text] [Related]
4. Hepatic secretion of conjugated drugs and endogenous substances.
Keppler D; König J
Semin Liver Dis; 2000; 20(3):265-72. PubMed ID: 11076395
[TBL] [Abstract][Full Text] [Related]
5. Octreotide inhibits the bilirubin carriers organic anion transporting polypeptides 1B1 and 1B3 and the multidrug resistance-associated protein 2.
Visentin M; Stieger B; Merz M; Kullak-Ublick GA
J Pharmacol Exp Ther; 2015 Nov; 355(2):145-51. PubMed ID: 26330539
[TBL] [Abstract][Full Text] [Related]
6. Construction of triple-transfected cells [organic anion-transporting polypeptide (OATP) 1B1/multidrug resistance-associated protein (MRP) 2/MRP3 and OATP1B1/MRP2/MRP4] for analysis of the sinusoidal function of MRP3 and MRP4.
Hirouchi M; Kusuhara H; Onuki R; Ogilvie BW; Parkinson A; Sugiyama Y
Drug Metab Dispos; 2009 Oct; 37(10):2103-11. PubMed ID: 19628752
[TBL] [Abstract][Full Text] [Related]
7. Increased hepatic and renal expressions of multidrug resistance-associated protein 3 in Eisai hyperbilirubinuria rats.
Kuroda M; Kobayashi Y; Tanaka Y; Itani T; Mifuji R; Araki J; Kaito M; Adachi Y
J Gastroenterol Hepatol; 2004 Feb; 19(2):146-53. PubMed ID: 14731123
[TBL] [Abstract][Full Text] [Related]
8. Vectorial transport of enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in rat and human livers.
Liu L; Cui Y; Chung AY; Shitara Y; Sugiyama Y; Keppler D; Pang KS
J Pharmacol Exp Ther; 2006 Jul; 318(1):395-402. PubMed ID: 16627748
[TBL] [Abstract][Full Text] [Related]
9. Evaluating the in vitro inhibition of UGT1A1, OATP1B1, OATP1B3, MRP2, and BSEP in predicting drug-induced hyperbilirubinemia.
Chang JH; Plise E; Cheong J; Ho Q; Lin M
Mol Pharm; 2013 Aug; 10(8):3067-75. PubMed ID: 23750830
[TBL] [Abstract][Full Text] [Related]
10. Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver.
van de Steeg E; Stránecký V; Hartmannová H; Nosková L; Hřebíček M; Wagenaar E; van Esch A; de Waart DR; Oude Elferink RP; Kenworthy KE; Sticová E; al-Edreesi M; Knisely AS; Kmoch S; Jirsa M; Schinkel AH
J Clin Invest; 2012 Feb; 122(2):519-28. PubMed ID: 22232210
[TBL] [Abstract][Full Text] [Related]
11. Uptake and efflux transporters for conjugates in human hepatocytes.
Keppler D
Methods Enzymol; 2005; 400():531-42. PubMed ID: 16399368
[TBL] [Abstract][Full Text] [Related]
12. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor.
Yamada A; Maeda K; Kamiyama E; Sugiyama D; Kondo T; Shiroyanagi Y; Nakazawa H; Okano T; Adachi M; Schuetz JD; Adachi Y; Hu Z; Kusuhara H; Sugiyama Y
Drug Metab Dispos; 2007 Dec; 35(12):2166-76. PubMed ID: 17823233
[TBL] [Abstract][Full Text] [Related]
13. OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker.
Nakagomi-Hagihara R; Nakai D; Kawai K; Yoshigae Y; Tokui T; Abe T; Ikeda T
Drug Metab Dispos; 2006 May; 34(5):862-9. PubMed ID: 16501004
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of OATP1B proteins correlates with hyperbilirubinemia in advanced cholestasis.
Sticova E; Lodererova A; van de Steeg E; Frankova S; Kollar M; Lanska V; Kotalova R; Dedic T; Schinkel AH; Jirsa M
Int J Clin Exp Pathol; 2015; 8(5):5252-62. PubMed ID: 26191226
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in bilirubin metabolism research: the molecular mechanism of hepatocyte bilirubin transport and its clinical relevance.
Kamisako T; Kobayashi Y; Takeuchi K; Ishihara T; Higuchi K; Tanaka Y; Gabazza EC; Adachi Y
J Gastroenterol; 2000; 35(9):659-64. PubMed ID: 11023036
[TBL] [Abstract][Full Text] [Related]
16. Fasiglifam (TAK-875) Inhibits Hepatobiliary Transporters: A Possible Factor Contributing to Fasiglifam-Induced Liver Injury.
Li X; Zhong K; Guo Z; Zhong D; Chen X
Drug Metab Dispos; 2015 Nov; 43(11):1751-9. PubMed ID: 26276582
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the endothelin receptor antagonists ambrisentan, bosentan, macitentan, and sitaxsentan as hepatobiliary transporter inhibitors and substrates in sandwich-cultured human hepatocytes.
Lepist EI; Gillies H; Smith W; Hao J; Hubert C; St Claire RL; Brouwer KR; Ray AS
PLoS One; 2014; 9(1):e87548. PubMed ID: 24498134
[TBL] [Abstract][Full Text] [Related]
18. Establishment of a set of double transfectants coexpressing organic anion transporting polypeptide 1B3 and hepatic efflux transporters for the characterization of the hepatobiliary transport of telmisartan acylglucuronide.
Ishiguro N; Maeda K; Saito A; Kishimoto W; Matsushima S; Ebner T; Roth W; Igarashi T; Sugiyama Y
Drug Metab Dispos; 2008 Apr; 36(4):796-805. PubMed ID: 18180273
[TBL] [Abstract][Full Text] [Related]
19. Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis.
Keitel V; Burdelski M; Warskulat U; Kühlkamp T; Keppler D; Häussinger D; Kubitz R
Hepatology; 2005 May; 41(5):1160-72. PubMed ID: 15841457
[TBL] [Abstract][Full Text] [Related]
20. [Analysis of xenobiotic detoxification system mediated by efflux transporters].
Suzuki H
Yakugaku Zasshi; 1999 Nov; 119(11):822-34. PubMed ID: 10590710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
